Check for updates

OPEN ACCESS

APPROVED BY Frontiers Editorial Office, Frontiers Media SA, Switzerland

*CORRESPONDENCE

Vincenzo Quagliariello ⊠ quagliariello.enzo@gmail.com Nicola Maurea ⊠ n.maurea@istitutotumori.na.it

SPECIALTY SECTION

This article was submitted to Cardio-Oncology, a section of the journal Frontiers in Cardiovascular Medicine

RECEIVED 22 December 2022 ACCEPTED 05 January 2023 PUBLISHED 19 January 2023

CITATION

Quagliariello V, Passariello M, Di Mauro A, Cipullo C, Paccone A, Barbieri A, Palma G, Luciano A, Buccolo S, Bisceglia I, Canale ML, Gallucci G, Inno A, De Lorenzo C and Maurea N (2023) Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways. *Front. Cardiovasc. Med.* 10:1129873. doi: 10.3389/fcvm.2023.1129873

COPYRIGHT

© 2023 Quagliariello, Passariello, Di Mauro, Cipullo, Paccone, Barbieri, Palma, Luciano, Buccolo, Bisceglia, Canale, Gallucci, Inno, De Lorenzo and Maurea. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).

The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways

Vincenzo Quagliariello^{1*}, Margherita Passariello^{2,3}, Annabella Di Mauro⁴, Ciro Cipullo⁴, Andrea Paccone¹, Antonio Barbieri⁵, Giuseppe Palma⁵, Antonio Luciano⁵, Simona Buccolo¹, Irma Bisceglia⁶, Maria Laura Canale⁷, Giuseppina Gallucci⁸, Alessandro Inno⁹, Claudia De Lorenzo^{2,3} and Nicola Maurea^{1*}

¹Division of Cardiology, Istituto Nazionale Tumori- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Fondazione G. Pascale, Naples, Italy, ²Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Naples, Italy, ³Ceinge-Biotecnologie Avanzate s.c.a.r.l., Naples, Italy, ⁴Pathology Unit, Istituto Nazionale Tumori- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Fondazione G. Pascale, Naples, Italy, ⁵Animal Facility, Istituto Nazionale Tumori- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)- Fondazione G. Pascale, Naples, Italy, ⁶Servizi Cardiologici Integrati, Dipartimento Cardio-Toraco-Vascolare, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy, ⁷U.O.C. Cardiologia, Ospedale Versilia, Lido di Camaiore (LU), Camaiore, Italy, ⁸Cardiologia, Centro di Riferimento Oncologico della Basilicata (CROB) - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rionero in Vulture, Italy, ⁹Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Sacro Cuore Don Calabria, Negrar, Italy

KEYWORDS

immunotherapy, biomarkers, preclinical study, mechanisms, inflammation, interleukin

A corrigendum on

Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways

by Quagliariello, V., Passariello, M., Di Mauro, A., Cipullo, C., Paccone, A., Barbieri, A., Palma, G., Luciano, A., Buccolo, S., Bisceglia, I., Canale, M. L., Gallucci, G., Inno, A., De Lorenzo, C., and Maurea, N. (2022). *Front. Cardiovasc. Med.* 9:930797. doi: 10.3389/fcvm.2022.930797

In the published article, there was an error in the **Data Availability** statement. The original statement incorrectly read: "The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation." The correct **Data Availability** statement appears below:

"The data presented in the study are deposited in the Zenodo repository, accession number https://zenodo.org/record/7040431#.YyMLcYrP1D9."

In the published article, there was an error in the **Funding** statement. The original statement incorrectly read: "This work was funded by a Ricerca Corrente grant from the Italian Ministry of Health." The correct **Funding** statement appears below:

"This work was funded by a "Ricerca Corrente" grant from the Italian Ministry of Health titled "Cardiotossicità da chemioterapie, targeted therapies e immunoterapie, diagnosi precoce e cardioprotezione, Ricerca preclinica e clinica".

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.